Krystal Biotech Inc | Trend line / H&SNASDAQ:KRYS (Krystal Biotech Inc)
Engages in developing and commercializing pharmaceutical products.
It offers the product, VYJUVEK.
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
4.30 EUR
86.13 M EUR
280.63 M EUR
24.86 M
About Krystal Biotech, Inc.
Sector
Industry
CEO
Krish S. Krishnan
Website
Headquarters
Pittsburgh
Founded
2016
ISIN
US5011471027
FIGI
BBG00MDVCTT0
Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. It offers the product, VYJUVEK. The company was founded by Krish S. Krishnan and Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Related stocks
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange Krystal Biotech, Inc. stocks are traded under the ticker 4KB.
We've gathered analysts' opinions on Krystal Biotech, Inc. future price: according to them, 4KB price has a max estimate of 218.87 EUR and a min estimate of 142.48 EUR. Watch 4KB chart and read a more detailed Krystal Biotech, Inc. stock forecast: see what analysts think of Krystal Biotech, Inc. and suggest that you do with its stocks.
Yes, you can track Krystal Biotech, Inc. financials in yearly and quarterly reports right on TradingView.
Krystal Biotech, Inc. is going to release the next earnings report on Nov 3, 2025. Keep track of upcoming events with our Earnings Calendar.
4KB earnings for the last quarter are 1.10 EUR per share, whereas the estimation was 1.01 EUR resulting in a 8.88% surprise. The estimated earnings for the next quarter are 0.93 EUR per share. See more details about Krystal Biotech, Inc. earnings.
Krystal Biotech, Inc. revenue for the last quarter amounts to 81.53 M EUR, despite the estimated figure of 78.07 M EUR. In the next quarter, revenue is expected to reach 79.41 M EUR.
4KB net income for the last quarter is 32.54 M EUR, while the quarter before that showed 33.03 M EUR of net income which accounts for −1.48% change. Track more Krystal Biotech, Inc. financial stats to get the full picture.
No, 4KB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Oct 22, 2025, the company has 275 employees. See our rating of the largest employees — is Krystal Biotech, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Krystal Biotech, Inc. EBITDA is 134.17 M EUR, and current EBITDA margin is 37.84%. See more stats in Krystal Biotech, Inc. financial statements.
Like other stocks, 4KB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Krystal Biotech, Inc. stock right from TradingView charts — choose your broker and connect to your account.